查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
微脂体开发及微脂体製造服务市场(2022年～2035年):各产品製剂类型，各产业规模，各终端用户业界，各主要地区:产业趋势与全球预测(2022年～2035年)
市场调查报告书
商品编码
1172475

微脂体开发及微脂体製造服务市场(2022年～2035年):各产品製剂类型，各产业规模，各终端用户业界，各主要地区:产业趋势与全球预测(2022年～2035年)

Liposome Development and Liposome Manufacturing Services Market, 2022-2035: Distribution by Type of Product Formulation, Scale of Operation, End User Industry, Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035
出版日期: | 出版商: Roots Analysis | 英文 226 Pages | 商品交期: 最快1-2个工作天内

价格

本报告提供全球微脂体开发及微脂体製造服务市场相关调查，市场概要，以及各产品製剂类型，各产业规模，各终端用户业界，各主要地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 序文

第2章 摘要整理

第3章 简介

  • 章概要
  • 微脂体的简介
  • 微脂体的形成
  • 微脂体的分类
  • 药物递输系统的微脂体
  • 微脂体的製作方法
  • 准备后的处理
  • 微脂体分析与表征
  • 微脂体的製药及产业的应用
  • 微脂体的开发与製造的课题
  • 微脂体的开发、製造的外包的必要性
  • 未来展望

第4章 市场市场形势:微脂体的开发及製造服务供应商

  • 章概要
  • 微脂体的开发及製造服务供应商的形势

第5章 企业简介

  • 章概要
  • 以北美作为据点的主要加入企业
  • 以欧洲作为据点的主要加入企业
  • 以亚太地区作为据点的主要加入企业

第6章 临床试验分析

  • 章概要
  • 范围与调查手法
  • 微脂体:临床试验分析

第7章 出版物的分析

第8章 专利分析

第9章 全球活动分析

第10章 外包:GO/NO-GO组成架构

第11章 市场预测机会分析

  • 章概要
  • 主要的假设与调查手法
  • 全球微脂体开发及製造服务市场，2022年～2035年

第12章 结论

第13章 执行见解

第14章 附录1:表格形式的资料

第15章 附录2:公司及组织的清单

Product Code: RA100400

INTRODUCTION

Around 90% of the drug candidates in the current development pipeline and close to 40% of marketed pharmacological products, have concerns related to solubility and / or permeability. Therefore, players engaged in the pharmaceutical industry are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, liposomes (which improve permeability across biological membranes), have garnered the attention of drug developers. Liposomes are small artificial vesicles that have the ability to encapsulate, deliver and release low-soluble drugs and small molecules to a specific site in the body. Over time, various research studies have demonstrated the potential of liposomes in disease diagnosis and drug delivery applications, owing to their ability to self-assemble, carry large drug payloads, act as biomarkers for various diseases and transport important functional elements. Given the various benefits, liposomes have gained significant interest in the biopharmaceutical industry, which is anticipated to increase their demand in future. However, the development and manufacturing of liposomes is associated with several challenges, including complex manufacturing processes, huge capital investments, inadequate clinical grade production and GMP compliant industrial scale-up, lack of facilities with necessary infrastructure, as well as concerns related to storage and stability. Therefore, considering the aforementioned challenges, a number of pharmaceutical companies have demonstrated the preference to outsource their respective liposome development and manufacturing operations to specialized service providers.

Q1. What is the current market landscape of the liposome development and manufacturing services market?

The liposome development and manufacturing services market is amongst one of the most dynamic sectors of the biopharmaceutical industry. Presently, more than 70 companies have the required capabilities to offer liposome development and manufacturing services across different geographical locations. These service providers employ a variety of analysis and characterization methods for liposome development.

Q2. How has outsourcing evolved in the liposome development and manufacturing domain?

The manufacturing of highly potent liposome-based therapeutics requires an adequate working environment (to prevent cross contamination within multi-product assets), stringent manufacturing protocols (to comply with the established regulatory standards) and a trained workforce (to satisfactorily handle highly potent materials). In addition, it requires an expensive infrastructure, which is often complex to engineer, install and maintain. As a result, various companies rely on third party service providers to leverage their technologies for manufacturing these therapeutics and achieve greater operational flexibility. The inherent expertise of CMOs is believed to be capable of enabling reduction in the time-to-market a product and offer significant cost-benefits.

Q3. What are the recent developments and expected trends in the liposome development and manufacturing domain?

In recent years, several events have been organized by various researchers / industry stakeholders in order to consolidate their presence in this field and enhance their existing capabilities to meet the growing demand for these novel drug delivery systems. It is worth mentioning that majority of the events were focused on discussing the analytical method development, manufacturing and process development steps for liposomes.

Q4. What are the key challenges faced by liposome development and manufacturing service providers?

The primary challenge faced by these service providers is associated with the poor stability of liposomes under shelf and in vivo conditions. This is mainly caused by the possibility of lipid oxidation and hydrolysis, leakage and loss of hydrophilic cargos, along with fission and fusion of particles. Currently, some of these issues can be overcome by experimenting with formulation adjuvants, including antioxidants, or post-preparation processing, such as freeze-thawing and freeze-drying. Further, since the manufacturing of liposomes on large-scale is a multi-step and multi-test process, therefore, innovation in this domain is essential in order to overcome the challenges.

Q5. What are the key value drivers in the liposome development and manufacturing services market?

The increasing demand for novel drug delivery systems for effective delivery has led to a rise in the number of liposome-based therapeutics in the overall biopharmaceutical development pipeline. In order to cater to the growing demand for such therapeutics, there is a requirement for safe manufacturing technologies. Although some biopharmaceutical companies have made considerable investments to establish in-house capabilities, the capital-intensive nature and specialized containment requirements make the role of contract manufacturers crucial, specifically for small and mid-sized developers.

Q6. What is the current market scenario and likely growth associated with the liposome development and manufacturing services domain?

The liposome development and manufacturing services market is anticipated to grow at a steady pace in the coming years. Among various other types of product formulations, the therapeutic formulations of liposomes are anticipated to capture the maximum share. Further, in terms of end-users, the pharmaceutical and biotechnology industry stakeholders are most likely to outsource their liposome development and manufacturing operations to service providers as these companies primarily employ liposomes at commercial scale for delivering drugs to the target sites. Specifically, in terms of geography, the liposome development and manufacturing services market in Latin America is likely to grow at a relatively faster pace in the long term.

SCOPE OF THE REPORT

The 'Liposome Development and Manufacturing Services Market, 2022-2035: Distribution by Type of Product Formulation (Therapeutic and Nutraceutical), Scale of Operation (Discovery / Research, Preclinical, Clinical and Commercial), End User Industry (Pharmaceutical and Biotechnology, Cosmetics, Food, Agricultural, Academic and Other Industries), Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America): Industry Trends and Global Forecasts, 2022-2035' report features an extensive study of the current market landscape and future potential of the liposome development and manufacturing services market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing liposome development and manufacturing services. Amongst other elements, the report includes:

  • A general overview of liposomes, along with information on the formation and classification of liposomes. Further, the chapter also lays emphasis on liposome as a drug delivery system, liposomal drug delivery platforms and therapeutic applications of liposomes in drug delivery. Additionally, it highlights the methods for liposome preparation, post-preparation treatments, liposome analysis and characterization methods, pharmaceutical and industrial applications of liposomes. Further, it also features a discussion on the challenges in this domain and need for outsourcing of liposome development and manufacturing operations.
  • A detailed assessment of the overall market landscape of liposome development and manufacturing service providers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, types of method(s) for liposome preparation, type of service(s) offered (formulation development, analytical method development, contract manufacturing, process development, quality control, GMP manufacturing, characterization, fill / finish, clinical and regulatory support, feasibility studies, screening and liposome conjugation), liposome bioconjugation target(s) (protein, small molecule, lipid, peptide, nucleic acid, vaccine antigen, vitamin, oligonucleotide, carbohydrate and mineral), scalability (small, mid and large), liposome analysis and characterization method(s) (stability analysis, encapsulation efficiency determination, size analysis, drug release kinetics, lipid content analysis, lamellarity analysis and permeability analysis), application(s) of liposomes (drug delivery, cancer therapy and gene therapy), scale of operation (discovery / research, preclinical, clinical and commercial) and end user industry (pharmaceutical and biotechnology, food, academic, cosmetics, agricultural and other industries).
  • Elaborate profiles of the prominent (shortlisted based on a proprietary criterion) players offering liposome development and manufacturing services, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), information on its service portfolio, recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical studies related to liposomes, highlighting prevalent trends across different parameters, such as trial registration year, trial status, trial registration year and patients enrolled, trial phase, type of sponsor / collaborator, study design, leading players (in terms of number of trials conducted), disease indication(s), popular therapeutic areas, type of treatment, emerging focus areas and regional distribution of trials (in terms of number of trials conducted and trial status).
  • A detailed review of more than 6,000 peer-reviewed, scientific articles related to research on liposomes, based on several relevant parameters, such as year of publication, application area(s), and emerging focus areas. The chapter also highlights the top journals (in terms of number of publications and impact factor).
  • An insightful analysis of the patents filed / granted for liposomes, since 2017, taking into consideration various relevant parameters, such as type of patent, patent publication year, granted patents and patent applications, geography, CPC symbols, emerging focus areas, type of organization, leading players (in terms of number of patents granted / filed) and patent characteristics. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
  • An in-depth analysis of recent events (webinars / conferences / seminars / workshops / symposiums / summits) that were organized for stakeholders in this domain, based on several relevant parameters, such as year of event, event platform, type of event, geography, evolutionary trends in event agenda, most active event organizers, active industry and non-industry players (in terms of number of events that each company participated in), seniority level of event speakers, affiliated department of event speakers, most active speakers (in terms of number of events) and a geographical mapping of upcoming events.
  • An insightful outsourcing: go / no-go framework analysis, highlighting the various factors that need to be taken into consideration by liposome developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, large and very large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the current opportunity and the future growth potential associated with the liposome development and manufacturing services market, over the coming years. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as type of product formulation (therapeutic and nutraceutical), scale of operation (discovery / research, preclinical, clinical and commercial), end user industry (pharmaceutical and biotechnology, cosmetics, food, agricultural, academic and other industries), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. The information is primarily useful for us to draw out our opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

  • Who are the key players offering liposome development and manufacturing services?
  • What is the evolving trend of publications focused on liposomes?
  • How many patents, related to liposomes, have been filed / granted in the past few years?
  • Which companies are actively involved in conducting clinical trials for liposomes?
  • What are the key agenda items being discussed in various global events / conferences related to liposomes?
  • How is the current and future market opportunity related to liposome development and manufacturing services, likely to be distributed across key market segments?

CHAPTER OUTLINES

  • Chapter 2: is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of liposome development and manufacturing services market and its likely evolution in the short-mid to long term.
  • Chapter 3: provides a brief overview of liposomes, featuring information on the formation and classification of liposomes. Further, the chapter also lays emphasis on liposome as a drug delivery system, liposomal drug delivery platforms and therapeutic applications of liposomes in drug delivery. Additionally, it highlights the methods for liposome preparation, post-preparation treatments, liposome analysis and characterization methods, pharmaceutical and industrial applications of liposomes. Further, it also features a discussion on the challenges in this domain and need for outsourcing of liposome development and manufacturing operations.
  • Chapter 4: presents an overview of the current market landscape of liposome development and manufacturing service providers, featuring a detailed analysis based on several parameters, such as year of establishment, company size (in terms of number of employees), region of headquarters, types of method(s) for liposome preparation, type of service(s) offered (formulation development, analytical method development, contract manufacturing, process development, quality control, GMP manufacturing, characterization, fill / finish, clinical and regulatory support, feasibility studies, screening and liposome conjugation), liposome bioconjugation target(s) (protein, small molecule, lipid, peptide, nucleic acid, vaccine antigen, vitamin, oligonucleotide, carbohydrate and mineral), scalability (small, mid and large), liposome analysis and characterization method(s) (stability analysis, encapsulation efficiency determination, size analysis, drug release kinetics, lipid content analysis, lamellarity analysis and permeability analysis), application(s) of liposomes (drug delivery, cancer therapy and gene therapy), scale of operation (discovery / research, preclinical, clinical and commercial) and end user industry (pharmaceutical and biotechnology, food, academic, cosmetics, agricultural and other industries).
  • Chapter 5: includes profiles of the key players (shortlisted based on a proprietary criterion) offering liposome development and manufacturing services, across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, its financial information (if available), details on its service portfolio, recent developments and an informed future outlook.
  • Chapter 6: provides information on more than 800 completed, ongoing and planned clinical studies of liposomes, based on different parameters, such as trial registration year, trial status, trial registration year and patients enrolled, trial phase, type of sponsor / collaborator, and study design. In addition, the chapter highlights leading industry and non-industry players (in terms of number of trials conducted), key indication(s), popular therapeutics area(s), type of treatment, emerging focus areas and regional distribution of trials (in terms of number of trials conducted and trial status).
  • Chapter 7: features a detailed review of more than 6,000 peer-reviewed, scientific articles related to research on liposomes, based on parameters, such as year of publication, application area(s), emerging focus areas, top authors, key journals (in terms of number of publications and impact factor).
  • Chapter 8: features an in-depth analysis of the patents that have been filed / granted for liposomes, since 2017. The analysis also highlights the key trends associated with the patents, such as the type of patent (granted patent, patent application and others), patent publication year, granted patents and patent applications, geography, CPC symbols, emerging focus areas, type of organization, leading players (in terms of number of patents granted / filed). In addition, it includes detailed patent benchmarking and valuation analysis based on patent characteristics.
  • Chapter 9: provides an analysis of recent events (webinars / conferences / seminars / workshops / symposiums / summits) related to liposomes that were organized / planned. It features an analysis based on year of event, event platform, type of event, geography, evolutionary trends in event agenda, most active event organizers, active industry and non-industry players (in terms of number of events that each company participated in), seniority level of event speakers, affiliated department of event speakers, most active speakers (in terms of number of events) and a geographical mapping of upcoming events.
  • Chapter 10: presents an insightful outsourcing: go / no-go framework analysis that highlights the various factors that need to be taken into consideration by liposome developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, large and very large), while taking the aforementioned decision.
  • Chapter 11: features a detailed market forecast of the likely growth of liposome development and manufacturing services market, till the year 2035. It also includes insights on the likely distribution of the current and forecasted opportunity across the type of product formulation (therapeutic and nutraceutical), scale of operation (discovery / research, preclinical, clinical and commercial), end user industry (pharmaceutical and biotechnology, cosmetics, food, agricultural, academic and other industries), key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America).
  • Chapter 12: is a summary of the overall report, presenting insights on the contemporary market trends and the likely evolution of the liposome development and manufacturing services market.
  • Chapter 13: provides the transcripts of the interviews conducted with senior representatives of renowned organizations that are engaged in the research related to liposomes.
  • Chapter 14: is an appendix, that contains tabulated data and numbers for all the figures provided in the report.
  • Chapter 15: is an appendix, that contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Introduction to Liposomes
  • 3.3. Formation of Liposomes
  • 3.4. Classification of Liposomes
  • 3.5. Liposome as a Drug Delivery System
    • 3.5.1. Liposomal Drug Delivery Platforms
    • 3.5.2. Therapeutic Applications of Liposomes in Drug Delivery
  • 3.6. Methods for Liposome Preparation
  • 3.7. Post-Preparation Treatments
    • 3.7.1. Freeze-Thawing
    • 3.7.2. Freeze-Drying
  • 3.8. Liposome Analysis and Characterization
  • 3.9. Pharmaceutical and Industrial Applications of Liposomes
    • 3.9.1. Drug Delivery
    • 3.9.2. Gene Delivery
    • 3.9.3. Vaccine Delivery
    • 3.9.4. Cancer Therapy
    • 3.9.5. Agricultural Industry
    • 3.9.6. Cosmetics
    • 3.9.7. Food Industry
  • 3.10. Challenges in Liposome Development and Manufacturing
  • 3.11. Need for Outsourcing of Liposome Development and Manufacturing
  • 3.12. Future Perspectives

4. MARKET LANDSCAPE: LIPOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

  • 4.1. Chapter Overview
  • 4.2. Liposome Development and Manufacturing Service Providers Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Region of Headquarters
    • 4.2.4. Analysis by Company Size and Region of Headquarters
    • 4.2.5. Analysis by Type of Method(s) Used for Liposome Preparation
    • 4.2.6. Analysis by Type of Service(s) Offered
    • 4.2.7. Analysis by Liposome Bioconjugation Target(s)
    • 4.2.8. Analysis by Scalability
    • 4.2.9. Analysis by Liposome Analysis and Characterization Method(s)
    • 4.2.10. Analysis by Application(s) of Liposomes
    • 4.2.11. Analysis by Type of Service(s) Offered, Application(s) and Product Formulation
    • 4.2.12. Analysis by Scale of Operation
    • 4.2.13. Analysis by End User Industry
    • 4.2.14. Analysis by Scale of Operation and End User Industry

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Key Players Based in North America
    • 5.2.1. Baxter BioPharma Solutions
      • 5.2.1.1. Company Overview
      • 5.2.1.2. Financial Information
      • 5.2.1.3. Service Portfolio
      • 5.2.1.4. Recent Developments and Future Outlook
    • 5.2.2. Charles River Laboratories
      • 5.2.2.1. Company Overview
      • 5.2.2.2. Financial Information
      • 5.2.2.3. Service Portfolio
      • 5.2.2.4. Recent Developments and Future Outlook
  • 5.3. Key Players Based in Europe
    • 5.3.1. Evonik
      • 5.3.1.1. Company Overview
      • 5.3.1.2. Financial Information
      • 5.3.1.3. Service Portfolio
      • 5.3.1.4. Recent Developments and Future Outlook
    • 5.3.2. Fresenius Kabi
      • 5.3.2.1. Company Overview
      • 5.3.2.2. Financial Information
      • 5.3.2.3. Service Portfolio
      • 5.3.2.4. Recent Developments and Future Outlook
    • 5.3.3. GEA
      • 5.3.3.1. Company Overview
      • 5.3.3.2. Financial Information
      • 5.3.3.3. Service Portfolio
      • 5.3.3.4. Recent Developments and Future Outlook
    • 5.3.4. Intertek
      • 5.3.4.1. Company Overview
      • 5.3.4.2. Financial Information
      • 5.3.4.3. Service Portfolio
      • 5.3.4.4. Recent Developments and Future Outlook
  • 5.4. Key Players Based in Asia-Pacific
    • 5.4.1. Fujifilm
      • 5.4.1.1. Company Overview
      • 5.4.1.2. Financial Information
      • 5.4.1.3. Service Portfolio
      • 5.4.1.4. Recent Developments and Future Outlook

6. CLINICAL TRIAL ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Liposomes: Clinical Trial Analysis
    • 6.3.1. Analysis by Trial Registration Year
    • 6.3.2. Analysis by Trial Status
    • 6.3.3. Analysis by Trial Registration Year and Trial Status
    • 6.3.4. Analysis by Trial Registration Year and Patients Enrolled
    • 6.3.5. Analysis by Trial Phase
    • 6.3.6. Analysis by Trial Phase and Patients Enrolled
    • 6.3.7. Analysis by Type of Sponsor / Collaborator
    • 6.3.8. Analysis by Study Design
    • 6.3.9. Most Active Industry Players: Analysis by Number of Trials
    • 6.3.10. Most Active Non-Industry Players: Analysis by Number of Trials
    • 6.3.11. Analysis by Disease Indication(s)
    • 6.3.12. Most Popular Therapeutic Areas: Analysis by Number of Trials
    • 6.3.13. Analysis by Type of Treatment
    • 6.3.14. Word Cloud Analysis: Emerging Focus Areas
    • 6.3.15. Analysis by Top Indications and Trial Phase
    • 6.3.16. Analysis by Top Indications and Leading Industry Players
    • 6.3.17. Geographical Analysis by Number of Clinical Trials
    • 6.3.18. Geographical Analysis by Number of Patients Enrolled

7. PUBLICATION ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Liposomes: Recent Publications
    • 7.3.1. Analysis by Year of Publication
    • 7.3.2. Analysis by Application Area(s)
    • 7.3.3. Word Cloud Analysis: Emerging Focus Areas
    • 7.3.4. Key Journals: Analysis by Number of Publications
    • 7.3.5. Key Journals: Analysis by Impact Factor
    • 7.3.6. Key Journals: Analysis by Year-wise Number of Publications

8. PATENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Liposomes: Patent Analysis
    • 8.3.1. Analysis by Patent Publication Year
    • 8.3.2. Analysis by Granted Patents and Patent Applications
    • 8.3.3. Analysis by Geography
    • 8.3.4. Analysis by CPC Symbols
    • 8.3.5. Word Cloud Analysis: Emerging Focus Areas
    • 8.3.6. Analysis by Type of Organization
    • 8.3.7. Leading Industry Players: Analysis by Number of Patents
    • 8.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 8.3.9. Leading Individual Assignees: Analysis by Number of Patents
  • 8.4. Liposomes: Patent Benchmarking Analysis
    • 8.4.1. Analysis by Patent Characteristics
  • 8.5. Liposomes: Patent Valuation Analysis
  • 8.6. Leading Patents: Analysis by Number of Citations

9. GLOBAL EVENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Liposome Development and Manufacturing: Global Events Analysis
    • 9.3.1. Analysis by Year of Event
    • 9.3.2. Analysis by Event Platform
    • 9.3.3. Analysis by Type of Event
    • 9.3.4. Analysis by Year of Event and Type of Event
    • 9.3.5. Analysis by Geography
    • 9.3.6. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
    • 9.3.7. Most Active Event Organizers
  • 9.4. Liposome Development and Manufacturing: Speaker Analysis
    • 9.4.1. Most Active Industry Players: Analysis by Number of Events
    • 9.4.2. Most Active Non-Industry Players: Analysis by Number of Events
    • 9.4.3. Analysis by Seniority Level of Event Speakers
    • 9.4.4. Analysis by Affiliated Department of Event Speakers
    • 9.4.5. Most Active Speakers: Analysis by Number of Events
  • 9.5. Geographical Mapping of Upcoming Events
  • 9.6. Concluding Remarks

10. OUTSOURCING: GO / NO-GO FRAMEWORK

  • 10.1. Chapter Overview
  • 10.2. Outsourcing: Go / No-Go Framework
  • 10.3. Liposome-based Therapeutic Developers Outsourcing: Go / No-Go Framework
    • 10.3.1. Key Parameters and Assumptions
    • 10.3.2. Methodology
    • 10.3.3. Results and Interpretations
      • 10.3.3.1. Very Small Companies
      • 10.3.3.2. Small Companies
      • 10.3.3.3. Mid-Sized Companies
      • 10.3.3.4. Large Companies
      • 10.3.3.5. Very Large Companies

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Global Liposome Development and Manufacturing Services Market, 2022-2035
    • 11.3.1. Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
      • 11.3.1.1. Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035
      • 11.3.1.2. Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035
    • 11.3.2. Liposome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
      • 11.3.2.1. Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035
      • 11.3.2.2. Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035
      • 11.3.2.3. Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035
      • 11.3.2.4. Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035
    • 11.3.3. Liposome Development and Manufacturing Services Market: Distribution by End User Industry, 2022 and 2035
      • 11.3.3.1. Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035
      • 11.3.3.2. Liposome Development and Manufacturing Services Market for Cosmetics, 2022-2035
      • 11.3.3.3. Liposome Development and Manufacturing Services Market for Food Industry, 2022 2035
      • 11.3.3.4. Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022 2035
      • 11.3.3.5. Liposome Development and Manufacturing Services Market for Academics, 2022 2035
      • 11.3.3.6. Liposome Development and Manufacturing Services Market for Other Industries, 2022 2035
    • 11.3.4. Liposome Development and Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
      • 11.3.4.1. Liposome Development and Manufacturing Services Market in North America, 2022-2035
      • 11.3.4.2. Liposome Development and Manufacturing Services Market in Europe, 2022-2035
      • 11.3.4.3. Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035
      • 11.3.4.4. Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035
      • 11.3.4.5. Liposome Development and Manufacturing Services Market in Latin America, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF TABLES

  • Table 3.1 Classification of Liposomes
  • Table 4.1 List of Liposome Development and Manufacturing Service Providers
  • Table 4.2 Liposome Development and Manufacturing Service Providers: Information on Type of Method(s) Used for Liposome Preparation
  • Table 4.3 Liposome Development and Manufacturing Service Providers: Information on Type of Service(s) Offered
  • Table 4.4 Liposome Development and Manufacturing Service Providers: Information on Liposome Bioconjugation Target(s)
  • Table 4.5 Liposome Development and Manufacturing Service Providers: Information on Scalability, and Liposome Analysis and Characterization Method(s)
  • Table 4.6 Liposome Development and Manufacturing Service Providers: Information on Application(s) and Scale of Operation
  • Table 4.7 Liposome Development and Manufacturing Service Providers: Information on End User Industry
  • Table 5.1 Liposome Service Providers: List of Companies Profiled
  • Table 5.2 Baxter BioPharma Solutions: Company Snapshot
  • Table 5.3 Baxter BioPharma Solutions: Service Portfolio
  • Table 5.4 Baxter BioPharma Solutions: Recent Developments and Future Outlook
  • Table 5.5 Charles River Laboratories: Company Snapshot
  • Table 5.6 Charles River Laboratories: Service Portfolio
  • Table 5.7 Charles River Laboratories: Recent Developments and Future Outlook
  • Table 5.8 Evonik: Company Snapshot
  • Table 5.9 Evonik: Service Portfolio
  • Table 5.10 Evonik: Recent Developments and Future Outlook
  • Table 5.11 Fresenius Kabi: Company Snapshot
  • Table 5.12 Fresenius Kabi: Service Portfolio
  • Table 5.13 GEA: Company Snapshot
  • Table 5.14 GEA: Service Portfolio
  • Table 5.15 Intertek: Company Snapshot
  • Table 5.16 Intertek: Service Portfolio
  • Table 5.17 Intertek: Recent Developments and Future Outlook
  • Table 5.18 Fujifilm: Company Snapshot
  • Table 5.19 Fujifilm: Service Portfolio
  • Table 5.20 Fujifilm: Recent Developments and Future Outlook
  • Table 8.1 Patent Analysis: Top CPC Sections
  • Table 8.2 Patent Analysis: Top Five CPC Symbols
  • Table 8.3 Patent Analysis: Top Six CPC Codes
  • Table 8.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 8.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 8.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 8.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 9.1 List of Global Events related to Liposome Development and Manufacturing
  • Table 14.1 Liposome Development and Manufacturing Service Providers: Distribution by Year of Establishment
  • Table 14.2 Liposome Development and Manufacturing Service Providers: Distribution by Company Size
  • Table 14.3 Liposome Development and Manufacturing Service Providers: Distribution by Region of Headquarters
  • Table 14.4 Liposome Development and Manufacturing Service Providers: Distribution by Location of Headquarters
  • Table 14.5 Liposome Development and Manufacturing Service Providers: Distribution by Company Size and Region of Headquarters
  • Table 14.6 Liposome Development and Manufacturing Service Providers: Distribution by Type of Method(s) Used for Liposome Preparation
  • Table 14.7 Liposome Development and Manufacturing Service Providers: Distribution by Type of Service(s) Offered
  • Table 14.8 Liposome Development and Manufacturing Service Providers: Distribution by Type of Liposome Bioconjugation Target(s)
  • Table 14.9 Liposome Development and Manufacturing Service Providers: Distribution by Scalability
  • Table 14.10 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Analysis and Characterization Method(s)
  • Table 14.11 Liposome Development and Manufacturing Service Providers: Distribution by Application(s) of Liposomes
  • Table 14.12 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation
  • Table 14.13 Liposome Development and Manufacturing Service Providers: Distribution by End User Industry
  • Table 14.14 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation and End User Industry
  • Table 14.15 Baxter BioPharma Solutions: Annual Revenues, 2017-H1 2022 (USD Billion)
  • Table 14.16 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
  • Table 14.17 Evonik: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Table 14.18 Fresenius Kabi: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Table 14.19 GEA: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Table 14.20 Intertek: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Table 14.21 Fujifilm: Annual Revenues, FY 2017-3M FY 2022 (JPY Trillion)
  • Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2022
  • Table 14.23 Clinical Trial Analysis: Distribution by Trial Status
  • Table 14.24 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2001-2022
  • Table 14.25 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
  • Table 14.26 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 14.27 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Table 14.28 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 14.29 Clinical Trial Analysis: Distribution by Study Design
  • Table 14.30 Most Active Industry Players: Distribution by Number of Trials
  • Table 14.31 Most Active Non-Industry Players: Distribution by Number of Trials
  • Table 14.32 Clinical Trial Analysis: Distribution by Disease Indication(s)
  • Table 14.33 Most Popular Therapeutic Areas: Distribution by Number of Trials
  • Table 14.34 Clinical Trial Analysis: Distribution by Type of Treatment
  • Table 14.35 Clinical Trial Analysis: Distribution by Top Indications and Trial Phase
  • Table 14.36 Clinical Trial Analysis: Distribution by Top Indications and Leading Industry Players
  • Table 14.37 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
  • Table 14.38 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Table 14.39 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
  • Table 14.40 Publication Analysis: Distribution by Application Area(s)
  • Table 14.41 Key Journals: Distribution by Number of Publications
  • Table 14.42 Key Journals: Distribution by Impact Factor
  • Table 14.43 Key Journals: Year-wise Distribution by Number of Publications
  • Table 14.44 Patent Analysis: Distribution by Type of Patent
  • Table 14.45 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
  • Table 14.46 Patent Analysis: Year-wise Distribution by Granted Patents and Patent Applications, 2017-2022
  • Table 14.47 Patent Analysis: Distribution by Geography
  • Table 14.48 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
  • Table 14.49 Leading Industry Players: Distribution by Number of Patents
  • Table 14.50 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 14.51 Leading Individual Assignees: Distribution by Number of Patents
  • Table 14.52 Patent Analysis: Distribution by Patents Age
  • Table 14.53 Liposomes: Patent Valuation Analysis
  • Table 14.54 Global Event Analysis: Cumulative Year-wise Trend, 2017-2022
  • Table 14.55 Global Event Analysis: Distribution by Event Platform
  • Table 14.56 Global Event Analysis: Distribution by Type of Event
  • Table 14.57 Global Event Analysis: Distribution by Year of Event and Type of Event
  • Table 14.58 Global Event Analysis: Distribution by Location of Events
  • Table 14.59 Most Active Organizers: Distribution by Number of Events
  • Table 14.60 Most Active Industry Players: Distribution by Number of Events
  • Table 14.61 Most Active Non-Industry Players: Distribution by Number of Events
  • Table 14.62 Seniority Level of Event Speakers: Distribution by Number of Events
  • Table 14.63 Affiliated Department of Event Speakers: Distribution by Number of Events
  • Table 14.64 Most Active Speakers: Distribution by Number of Events
  • Table 14.65 Global Liposome Development and Manufacturing Services Market, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.66 Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
  • Table 14.67 Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.68 Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.69 Liposome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
  • Table 14.70 Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.71 Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.72 Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.73 Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.74 Liposome Development and Manufacturing Services Market: Distribution by End User Industry, 2022 and 2035
  • Table 14.75 Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.76 Liposome Development and Manufacturing Services Market for Cosmetics, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.77 Liposome Development and Manufacturing Services Market for Food Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.78 Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.79 Liposome Development and Manufacturing Services Market for Academics, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.80 Liposome Development and Manufacturing Services Market for Other Industries, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.81 Liposome Development and Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
  • Table 14.82 Liposome Development and Manufacturing Services Market in North America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.83 Liposome Development and Manufacturing Services Market in Europe, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.84 Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.85 Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
  • Table 14.86 Liposome Development and Manufacturing Services Market in Latin America, 2022-2035: Conservative, Base and Optimistic Scenarios (USD Billion)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Liposome Development and Manufacturing Service Providers Landscape
  • Figure 2.2 Executive Summary: Clinical Trial Analysis
  • Figure 2.3 Executive Summary: Publication Analysis
  • Figure 2.4 Executive Summary: Patent Analysis
  • Figure 2.5 Executive Summary: Global Event Analysis
  • Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Formation of Liposomes
  • Figure 3.2 Liposomal Drug Delivery Platforms
  • Figure 3.3 Therapeutic Applications of Liposomes in Drug Delivery
  • Figure 3.4 Methods for Liposome Preparation
  • Figure 3.5 Liposomal Analysis and Characterization Methods
  • Figure 3.6 Pharmaceutical and Industrial Applications of Liposomes
  • Figure 4.1 Liposome Development and Manufacturing Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Liposome Development and Manufacturing Service Providers: Distribution by Company Size
  • Figure 4.3 Liposome Development and Manufacturing Service Providers: Distribution by Region of Headquarters
  • Figure 4.4 Liposome Development and Manufacturing Service Providers: Distribution by Location of Headquarters
  • Figure 4.5 Liposome Development and Manufacturing Service Providers: Distribution by Company Size and Region of Headquarters
  • Figure 4.6 Liposome Development and Manufacturing Service Providers: Distribution by Type of Method(s) Used for Liposome Preparation
  • Figure 4.7 Liposome Development and Manufacturing Service Providers: Distribution by Type of Service(s) Offered
  • Figure 4.8 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Bioconjugation Target(s)
  • Figure 4.9 Liposome Development and Manufacturing Service Providers: Distribution by Scalability
  • Figure 4.10 Liposome Development and Manufacturing Service Providers: Distribution by Liposome Analysis and Characterization Method(s)
  • Figure 4.11 Liposome Development and Manufacturing Service Providers: Distribution by Application(s) of Liposomes
  • Figure 4.12 Liposome Development and Manufacturing Service Providers: Distribution by Type of Service(s) Offered, Application(s) and Product Formulation
  • Figure 4.13 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation
  • Figure 4.14 Liposome Development and Manufacturing Service Providers: Distribution by End User Industry
  • Figure 4.15 Liposome Development and Manufacturing Service Providers: Distribution by Scale of Operation and End User Industry
  • Figure 5.1 Baxter BioPharma Solutions: Annual Revenues, 2017-H1 2022 (USD Billion)
  • Figure 5.2 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
  • Figure 5.3 Evonik: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Figure 5.4 Fresenius Kabi: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Figure 5.5 GEA: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Figure 5.6 Intertek: Annual Revenues, 2017-H1 2022 (EUR Billion)
  • Figure 5.7 Fujifilm: Annual Revenues, FY 2017-3M FY 2022 (JPY Trillion)
  • Figure 6.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2022
  • Figure 6.3 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 6.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2001-2022
  • Figure 6.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
  • Figure 6.6 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 6.7 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Figure 6.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 6.9 Clinical Trial Analysis: Distribution by Study Design
  • Figure 6.10 Most Active Industry Players: Distribution by Number of Trials
  • Figure 6.11 Most Active Non-Industry Players: Distribution by Number of Trials
  • Figure 6.12 Clinical Trial Analysis: Distribution by Disease Indication(s)
  • Figure 6.13 Most Popular Therapeutic Areas: Distribution by Number of Trials
  • Figure 6.14 Clinical Trial Analysis: Distribution by Type of Treatment
  • Figure 6.15 Word Cloud Analysis: Emerging Focus Areas
  • Figure 6.16 Clinical Trial Analysis: Distribution by Top Indications and Trial Phase
  • Figure 6.17 Clinical Trial Analysis: Distribution by Top Indications and Leading Industry Players
  • Figure 6.18 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
  • Figure 6.19 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Figure 7.1 Publication Analysis: Cumulative Year-wise Trend, 2017-2022
  • Figure 7.2 Publication Analysis: Distribution by Application Area(s)
  • Figure 7.3 Word Cloud Analysis: Emerging Focus Areas
  • Figure 7.4 Key Journals: Distribution by Number of Publications
  • Figure 7.5 Key Journals: Distribution by Impact Factor
  • Figure 7.6 Key Journals: Year-wise Distribution by Number of Publications
  • Figure 8.1 Patent Analysis: Distribution by Type of Patent
  • Figure 8.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
  • Figure 8.3 Patent Analysis: Year-wise Distribution by Granted Patents and Patent Applications, 2017-2022
  • Figure 8.4 Patent Analysis: Distribution by Geography
  • Figure 8.5 Patent Analysis: Distribution by CPC Sections
  • Figure 8.6 Word Cloud Analysis: Emerging Focus Areas
  • Figure 8.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
  • Figure 8.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 8.9 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 8.10 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 8.11 Leading Players: Benchmarking by Patent Characteristics (CPC Codes)
  • Figure 8.12 Patent Analysis: Distribution by Patent Age
  • Figure 8.13 Liposomes: Patent Valuation Analysis
  • Figure 9.1 Global Event Analysis: Cumulative Year-wise Trend, 2017-2022
  • Figure 9.2 Global Event Analysis: Distribution by Event Platform
  • Figure 9.3 Global Event Analysis: Distribution by Type of Event
  • Figure 9.4 Global Event Analysis: Distribution by Year of Event and Type of Event
  • Figure 9.5 Global Event Analysis: Distribution by Location of Events
  • Figure 9.6 Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area
  • Figure 9.7 Global Event Analysis: Historical Trend of Event Agendas, 2017-2022
  • Figure 9.8 Most Active Organizers: Distribution by Number of Events
  • Figure 9.9 Most Active Industry Players: Distribution by Number of Events
  • Figure 9.10 Most Active Non-Industry Players: Distribution by Number of Events
  • Figure 9.11 Seniority Level of Event Speakers: Distribution by Number of Events
  • Figure 9.12 Affiliated Department of Event Speakers: Distribution by Number of Events
  • Figure 9.13 Most Active Speakers: Distribution by Number of Events
  • Figure 9.14 Global Event Analysis: Geographical Mapping of Upcoming Events
  • Figure 10.1 Outsourcing: Go / No-Go Framework
  • Figure 10.2 Outsourcing: Go / No-Go Framework Methodology
  • Figure 10.3 Outsourcing: Go / No-Go Framework for Liposome-based Therapeutic Developers
  • Figure 10.4 Liposome-based Therapeutic Developers: Benchmarking of Very Small Companies
  • Figure 10.5 Liposome-based Therapeutic Developers: Benchmarking of Small Companies
  • Figure 10.6 Liposome-based Therapeutic Developers: Benchmarking of Mid-Sized Companies
  • Figure 10.7 Liposome-based Therapeutic Developers: Benchmarking of Large Companies
  • Figure 10.8 Liposome-based Therapeutic Developers: Benchmarking of Very Large Companies
  • Figure 11.1 Global Liposome Development and Manufacturing Services Market, 2022-2035 (USD Billion)
  • Figure 11.2 Liposome Development and Manufacturing Services Market: Distribution by Type of Product Formulation, 2022 and 2035
  • Figure 11.3 Liposome Development and Manufacturing Services Market for Therapeutics, 2022-2035 (USD Billion)
  • Figure 11.4 Liposome Development and Manufacturing Services Market for Nutraceuticals, 2022-2035 (USD Billion)
  • Figure 11.5 Liposome Development and Manufacturing Services Market: Distribution by Scale of Operation, 2022 and 2035
  • Figure 11.6 Liposome Development and Manufacturing Services Market for Discovery / Research Scale of Operation, 2022-2035 (USD Billion)
  • Figure 11.7 Liposome Development and Manufacturing Services Market for Preclinical Scale of Operation, 2022-2035 (USD Billion)
  • Figure 11.8 Liposome Development and Manufacturing Services Market for Clinical Scale of Operation, 2022-2035 (USD Billion)
  • Figure 11.9 Liposome Development and Manufacturing Services Market for Commercial Scale of Operation, 2022-2035 (USD Billion)
  • Figure 11.10 Liposome Development and Manufacturing Services Market: Distribution by End User Industry, 2022 and 2035
  • Figure 11.11 Liposome Development and Manufacturing Services Market for Pharmaceutical and Biotechnology Industry, 2022-2035 (USD Billion)
  • Figure 11.12 Liposome Development and Manufacturing Services Market for Cosmetics, 2022-2035 (USD Billion)
  • Figure 11.13 Liposome Development and Manufacturing Services Market for Food Industry, 2022-2035 (USD Billion)
  • Figure 11.14 Liposome Development and Manufacturing Services Market for Agricultural Industry, 2022-2035 (USD Billion)
  • Figure 11.15 Liposome Development and Manufacturing Services Market for Academics, 2022-2035 (USD Billion)
  • Figure 11.16 Liposome Development and Manufacturing Services Market for Other Industries, 2022-2035 (USD Billion)
  • Figure 11.17 Liposome Development and Manufacturing Services Market: Distribution by Key Geographical Regions, 2022 and 2035
  • Figure 11.18 Liposome Development and Manufacturing Services Market in North America, 2022-2035 (USD Billion)
  • Figure 11.19 Liposome Development and Manufacturing Services Market in Europe, 2022-2035 (USD Billion)
  • Figure 11.20 Liposome Development and Manufacturing Services Market in Asia-Pacific, 2022-2035 (USD Billion)
  • Figure 11.21 Liposome Development and Manufacturing Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
  • Figure 11.22 Liposome Development and Manufacturing Services Market in Latin America, 2022-2035 (USD Billion)
  • Figure 12.1 Concluding Remarks: Liposome Development and Manufacturing Service Providers Landscape
  • Figure 12.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 12.3 Concluding Remarks: Publication Analysis
  • Figure 12.4 Concluding Remarks: Patent Analysis
  • Figure 12.5 Concluding Remarks: Global Event Analysis
  • Figure 12.6 Concluding Remarks: Market Forecast and Opportunity Analysis